Login to Your Account



Pharma: Other News to note


Friday, January 10, 2014
Allergan Inc., of Irvine, Calif., said Botox (onabotulinumtoxinA) received a license from the UK’s Medicines and Healthcare products Regulatory Agency for the temporary improvement in the appearance of moderate to severe lateral canthal lines (crow’s feet lines) seen at maximum smile, either alone or when treated at the same time as glabellar (or frown) lines seen at maximum frown, in adult patients where those facial lines have an important psychological impact.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription